Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 207   

Articles published

SNY 53.17 -0.22 (-0.41%)
price chart
From Oakmark's Market Beaters: Value + Income
Both spirit maker Diageo (DEO) and pharma manufacturer Sanofi (SNY) were deemed to still be trading at deep discounts to intrinsic value.
DRug Active runners: Pfizer Inc. (NYSE:PFE), Sanofi SA (ADR) (NYSE:SNY ...
Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) In For Interesting Times
Boston, MA, 03/31/2014 (usastockreports)- Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015.
Avoid Applied Genetic Technologies IPO [Sanofi SA (ADR), BioMarin ...
AGTC is a clinical-stage biotechnology firm, developing treatments for severe inherited diseases of the eye. AGTC plans to raise $50.0 million in its upcoming IPO, offering 3.6 million shares at an expected price range of $13-$15 per share.
Related articles »  
Stocks in the Spotlight - Edwards Lifesciences Corp(NYSE:EW), Sanofi SA (ADR ...
Sanofi SA (ADR)(NYSE:SNY) recently declared that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking ...
Related articles »  
Notable Movers - Sanofi SA (ADR) (NYSE:SNY), Thermo Fisher Scientific Inc ...
Las Vegas, NV - 07 April 2014 - (Tech Sonian) - Sanofi SA (ADR) (NYSE:SNY) declared that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of Adacel´┐Ż (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular ...
NYSE unusual Volume: Sanofi SA (NYSE:SNY), Hawaiian Electric Industries ...
Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015.
Healthcare Active runners: Teva Pharmaceutical Industries (NYSE:TEVA ...  Tech News
Related articles »  
Even simple pregnancy tests can run into problems
Providing a superb example of the ever-changing biomedical landscape for even the most mundane of diagnostics, researchers at Washington University School of Medicine find that some commonly-used urine pregnancy tests lose their negative predictive ...
Related articles »  
Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi?
Lyxumia (lixisenatide) for the treatment of type 2 diabetes is once-daily GLP-1 from Sanofi's (SAN) stable. It is a potential head to head competitor to Novo Nordisk's (NVO) Victoza ($2.1b - 2013 annual sales).
How Stocks Taste Ups And Down- SunPower (NASDAQ:SPWR), Sanofi (NYSE ...
Genzyme, a Sanofi SA (ADR) (NYSE:SNY) [Trend Analysis] declared that 18 poster as well as oral presentations featuring Aubagio (teriflunomide) and Lemtrada (alemtuzumab) will be presented during the 66th American Academy of Neurology Annual ...